Ground News

Don't Just Read the News, Understand It.

pharmatimes.com image

News from pharmatimes.com

Your destination for news from pharmatimes.com. See how pharmatimes.com’s media bias impacts the breaking news stories of today.

We’ve discovered 65 headlines written by pharmatimes.com during the past 3 months.

pharmatimes.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is pharmatimes.com credible or reliable? Our Factuality score answers both of those questions. When it comes to pharmatimes.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about pharmatimes.com

Where is pharmatimes.com located?pharmatimes.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top pharmatimes.com News

Pregnancy: No Reason Not to Treat Migraine

European Parliament

Pregnancy: No Reason Not to Treat Migraine

100% Right coverage: 1 sources

Sumatriptan and onabotulinumtoxinA are safe options during pregnancy.See the Story

Bispecific Antibodies in the Treatment of Multiple Myeloma

Bispecific Antibodies in the Treatment of Multiple Myeloma

100% Center coverage: 1 sources

The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal antibodies like daratumumab along with proteasome inhibitors (PI)s, and immune modulators (IMiD)s have significantly improved survival and outcomes, but also cause unique challenges at the time of relapse. Engaging immune T cells for tumour cell kill with chimeric antigenic T-cell (CAR T-cell) therapy and bispecific antibodies have become important therapeutic op…See the Story

Three-Year Data Reveals Long-Term Power of Bimekizumab for PsA

Three-Year Data Reveals Long-Term Power of Bimekizumab for PsA

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.See the Story

eXmoor and Signadori Bio enter cell therapy partnership

Signadori is advancing a platform designed to overcome the challenges of treating solid cancers Read Article

Clinical Trial Success: Efgartigimod Achieves 79% Response Rate in Myositis, Earns FDA Fast Track for Sjogren's

New Phase 2 data reveals significant TIS improvement of 50.45 vs 35.65 in myositis patients. FDA grants Fast Track status for Sjogren's disease program. See full results.Disease · Belgium See the Story

Teva and Fosun Pharma partner on early-stage oncology drug

The candidate is being evaluated as both a monotherapy and in combination pembrolizumab Read Article

EDX medical partners with spire healthcare to advance disease diagnostics

Collaboration aims to improve rapid detection and personalised treatmentsUnited Kingdom · United Kingdom Read Article

Levicept presents new LEVI-04 data at EULAR

Biotech firm shares phase 2 findings on novel osteoarthritis treatmen Read Article

Tagomics awarded £860 k Innovate UK Biomedical Catalyst grant for detection of colorectal cancer

100% Center coverage: 1 sources

Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860 k Innovate UK funding as part of the Biomedical Catalyst program for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics.Cancer · United Kingdom See the Story

PharmaTimes Clinical Researcher of the Year – The Americas

Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!Read Article

New Funding Boosts Development of Rapid Test for Sexually Transmitted Infections

100% Center coverage: 1 sources

Birmingham spin-out Linear Diagnostics has been awarded £1m funding to finalizse the development of a rapid test for sexually transmitted infections (STIs), in partnership with the NIHR HealthTech Research Centre (HRC) in Diagnostic and Technology Evaluation and the North East Innovation Lab, part of Newcastle Hospitals.United Kingdom · United Kingdom See the Story

Breaking News Topics Related to pharmatimes.com